PHARMACEUTICAL COMPANIES BY REVENUES IN 202O
The other big biopharmaceutical companies are Teva, Takeda, Baxter, Mylan, and Merck group.
JOHNSON AND JOHNSON
Q1 RESULTS OF JOHNSON AND JOHNSON
Johnson and Johnson announced sales of $20.7 billion in the first quarter of 2020,
showing an operational growth of 3.3%. The sales from pharmaceuticals accounted for $11.13 billion, with an increase of 8.7%. However, the company has reported a decline in the sales of medical devices.
Stelara revenue grew by 10.2% (indicated for immune-mediated inflammatory diseases). Other growth drivers were Darzalex (indicated for multiple myeloma), Imbruvica (indicated for B-cell malignancies), Ingega (indicated for schizophrenia), Erleada (indicated for prostate cancer), Opsumit (indicated for pulmonary arterial hypertension), Tremfya (indicated for psoriasis), and Prezista (indicated for HIV infection).
Read on Denmark Healthcare System
Q2 SALES OF JOHNSON AND JOHNSON
Johnson and Johnson announced sales of $ 18.34 billion in the second quarter of 2020. The sales were reduced by 10.8% compared to the sales of 2019 ($ 20.56 bn). COVID19 pandemic impacted sales.
Pharmaceutical sales grew by 3.9%. The sales were driven by Stelara, Darzalex, Imbruvica, Erleada, Tremfya, Uptravi, and Opsumit. The sales were impacted by the biosimilar competition of Remicade and generics of Velcade and Zytiga.
The sales of medical devices were declined by 32.5%, and consumer health decreased by 3.4%.
Q3 SALES OF JOHNSON AND JOHNSON
Johnson and Johnson announced positive results in Q3 of 2020. The company has announced an increase in sales of 1.7%. The company has reported $21.08 billion sales in Q3 of 2020 compared to the $20.73 billion in Q3 of 2019.
The pharmaceutical segment sales were increased by 5.0%. Pharmaceutical sales were $11.42 billion in Q3 of 2020 compared to $10.88 billion in Q3 2019. The sales were primarily driven by Stelara ($ 1.31 billion), Trevicta ($ 0.93 billion), Darzalex ($ 1.1 billion), and Imbruvica ($ 1.03 billion).
Q4 SALES OF JOHNSON AND JOHNSON
In the fourth quarter, Johnson and Johnson have reported $22.5 billion in sales, an increase of 8.3% compared to the previous year. The pharmaceutical sector has driven the growth; increased the revenues by 16.3%.
Overall in 2020, Johnson and Johnson reported revenues of $ 82.6 billion. The pharmaceuticals segment contributed to 45.57 billion, followed by medical devices ($ 22.96 billion).
ROCHE
Q1 RESULTS OF ROCHE
Roche reported sales of $16.3 billion in the first quarter of 2020. The sales of pharmaceuticals were increased by 7%; the growth drivers were Tecentriq, Hemlibra, Ocrevus, and Perjeta.
The sales in the US grew by 3%, and in Europe, sales increased by 14% because of the strong demand for Tecentriq, Ocrevus, Perjeta, Hemlibra, Actemra/RoActemra, and Kadcyla. In Japan, sales grew by 3%.
The sales of diagnostics were increased by 5%.
Q2 RESULTS OF ROCHE
Roche announced that its second-quarter sales were significantly impacted because of COVID19. There was a 4% decline in sales in the second quarter. In May, the sales were dropped by 15%; however, they increased by 3% in June.
Avastin biosimilars are expected to enter the European market in the second half of 2020. A drop of 18% of sales in the first half of 2020 was reported due to biosimilars competition in the US and Japan.
In the first six months, Ocrevus ($ 2.26 bn) sales increased by 15%, Perjeta ($2 bn) sales increased by 17%, Tecentriq ($1.4 bn) sales increased by 75%, and Hemlibra ($1.2 bn) sales increased by 94%.
ANNUAL OVERVIEW OF ROCHE
In 2020, Roche reported an increase of 1% in sales at a constant exchange rate; pharmaceutical division sales dropped by 2%. The diagnostics division grow by 14% for the full year. The group is facing severe competition because of the biosimilars.
Ocrevus sales were increased by 24% and reported sales of $ 4.78 billion
Perjeta sales increased by 18%, with reported sales of $ 4.34 billion
Tecentriq ($ 3.00 billion), Hemlibra ($ 2.45 billion), Kadcyla ($ 1.9 billion), Alecensa ($ 1.33 billion), and Esbriet ($ 1.22 billion) are some of the other best selling products of Roche
Avastin sales dropped by 25% because of the biosimilar competition in the US, Europe, and Japan
MabThera sales were dropped by 31%, with reported sales of $ 4.67 billion
Xolair sales increased by 2%. The company reported sales of $ 2.11 billion
Lucentis sales dropped by 16% because of the COVID pandemic
Read on Denmark Healthcare System
NOVARTIS
Q1 RESULTS OF NOVARTIS
Novartis reported strong performance in Q1, with sales increased by 13%. The sales were primarily driven by Entresto USD 569 million, Zolgensma USD 170 million, Cosentyx USD 930 million, Kisqali USD 161 million, and Piqray USD 74 million.
Q2 RESULTS OF NOVARTIS
Novartis announced that net sales were decreased by 1%. COVID19 pandemic has impacted sales, especially ophthalmology products.
ANNUAL OVERVIEW OF NOVARTIS
Novartis sales increased by 3% in 2020. The sales were primarily driven by Cosentyx ($ 3.99 billion), Gilenya ($ 3.00 billion), Entresto ($ 2.50 billion), Tasigna ($ 1.96 billion), Lucentis ($ 1.93 billion), Revolade ($ 1.74 billion), Tafinlar + Mekinist ($ 1.54 billion), Sandostatin ($ 1.44 billion), Jakavi ($ 1.34 billion), Xolair ($ 1.25 billion), Gleevec ($ 1.19 billion), and Votubia ($ 1.08 billion).
The company’s ambitious product, Zolgensma reported sales of $ 0.92 billion.
Read on Denmark Healthcare System
MERCK
Q1 RESULTS OF MERCK
Merck reported sales of $ 12.1 billion, an increase of 11%. Keytruda revenues were $ 3.3 billion; sales increased by 46%. Revenues from vaccines were $ 2.2 billion. Januvia sales dropped by 6%; sales reported were $ 1.28 billion.
Q2 RESULTS OF MERCK
Revenues in the second quarter were $10.9 billion; the sales decreased by 8%. Keytruda sales grew by 29%; the company reported sales of $ 3.4 billion.
Q3 RESULTS OF MERCK
Merck reported sales of $ 12.6 billion, an increase of 1%. The revenues from Keytruda was $ 3.7 billion, an increase of 21%.
Q4 RESULTS OF MERCK
Merck reported sales of 12.5 billion in the fourth quarter, an increase of 5% compared to the previous year.
In 2020, Merck reported revenues of $ 48 billion. Keytruda sales contributed to 30% of the company’s revenues; the product sales increased by 30% to $ 14.4 billion.
Read on Denmark Healthcare System
PFIZER
Q1 RESULTS OF PFIZER
Pfizer revenues were dropped by 7% because of the decrease in the sales of consumer products. The biopharma revenues were increased by 12%, primarily because of Eliquis, Vyndaqel, Ibrance, and Inlyta.
Q2 RESULTS OF PFIZER
In the second quarter, the sales were dropped by 9%, 6% operational growth was reported from biopharmaceuticals. The sales in the second quarter were driven by Vyndaqel/Vyndamax, Eliquis, Ibrance, Inlyta, and Xtandi.
The H1 sales were dropped by 10%.
Read on Denmark Healthcare System
For pipeline, market overview, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com
For all syndicate reports: Click here
Comments